 - No more than 3 prior chemotherapy-inclusive regimens for locally advanced andor metastatic disease no limit on prior hormonal therapies or targeted anticancer therapies such as mechanistic target of rapamycin mTOR or CDK46 inhibitors, immune-oncology agents, tyrosine kinase inhibitors, or monoclonal antibodies against CTL4 or VEGF 